SSY GROUP (02005) obtained the drug production registration approval for Tartro Tero extended-release capsules (4mg).

The SSY Group (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for Tartaric Acid Tolterodine Sustained Release Capsules (4mg), which belongs to the category 4 of chemical drugs. The approval was granted through a consistency evaluation, making the group the third domestic company to receive approval. Tartaric Acid Tolterodine Sustained Release Capsules are mainly used for the treatment of overactive bladder syndrome.